Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Verrica Pharmaceuticals ( (VRCA) ) is now available.
On July 22, 2025, Verrica Pharmaceuticals Inc. filed a Certificate of Amendment to implement a 1-for-10 reverse stock split, effective July 24, 2025. This move, approved by stockholders on June 5, 2025, will proportionately adjust stock options and warrants, affecting all stockholders equally without changing percentage ownership. The company’s common stock will trade on a split-adjusted basis on The Nasdaq Global Market starting July 25, 2025, reducing the number of outstanding shares from approximately 92.5 million to 9.25 million.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals faces severe financial challenges, significantly impacting the overall score. Despite technical indicators showing moderate strength and positive corporate events, the financial distress and negative valuation metrics are dominant concerns.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of dermatological treatments. The company is known for its innovative solutions targeting skin diseases and conditions, aiming to address unmet medical needs in dermatology.
Average Trading Volume: 431,221
Technical Sentiment Signal: Sell
Current Market Cap: $66.78M
See more data about VRCA stock on TipRanks’ Stock Analysis page.